1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018, 68(6):394-424.
2. Simard EP, Ward EM, Siegel R, Jemal A: Cancers with increasing incidence trends in the United States: 1999 through 2008. CA: a cancer journal for clinicians 2012, 62(2):118-128.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA: a cancer journal for clinicians 2011, 61(2):69-90.
4. Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009, 27(9):1485-1491.
5. Bruix J, Colombo M: Hepatocellular carcinoma: current state of the art in diagnosis and treatment. Best practice & research Clinical gastroenterology 2014, 28(5):751.
6. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ: Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. The New England journal of medicine 2003, 348(17):1625-1638.
7. Center MM, Jemal A: International trends in liver cancer incidence rates. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2011, 20(11):2362-2368.
8. Creutz CE, Tomsig JL, Snyder SL, Gautier MC, Skouri F, Beisson J, Cohen J: The copines, a novel class of C2 domain-containing, calcium-dependent, phospholipid-binding proteins conserved from Paramecium to humans. The Journal of biological chemistry 1998, 273(3):1393-1402.
9. Tomsig JL, Creutz CE: Biochemical characterization of copine: a ubiquitous Ca2+-dependent, phospholipid-binding protein. Biochemistry 2000, 39(51):16163-16175.
10. Tomsig JL, Creutz CE: Copines: a ubiquitous family of Ca(2+)-dependent phospholipid-binding proteins. Cellular and molecular life sciences : CMLS 2002, 59(9):1467-1477.
11. Tomsig JL, Snyder SL, Creutz CE: Identification of targets for calcium signaling through the copine family of proteins. Characterization of a coiled-coil copine-binding motif. The Journal of biological chemistry 2003, 278(12):10048-10054.
12. Yang W, Ng P, Zhao M, Wong TK, Yiu SM, Lau YL: Promoter-sharing by different genes in human genome--CPNE1 and RBM12 gene pair as an example. BMC genomics 2008, 9:456.
13. Ilacqua AN, Price JE, Graham BN, Buccilli MJ, McKellar DR, Damer CK: Cyclic AMP signaling in Dictyostelium promotes the translocation of the copine family of calcium-binding proteins to the plasma membrane. BMC cell biology 2018, 19(1):13.
14. Shao Z, Ma X, Zhang Y, Sun Y, Lv W, He K, Xia R, Wang P, Gao X: CPNE1 predicts poor prognosis and promotes tumorigenesis and radioresistance via the AKT singling pathway in triple-negative breast cancer. Molecular carcinogenesis 2020, 59(5):533-544.
15. Liu S, Tang H, Zhu J, Ding H, Zeng Y, Du W, Ding Z, Song P, Zhang Y, Liu Z et al: High expression of Copine 1 promotes cell growth and metastasis in human lung adenocarcinoma. International journal of oncology 2018, 53(6):2369-2378.
16. Liang J, Zhang J, Ruan J, Mi Y, Hu Q, Wang Z, Wei B: CPNE1 Is a Useful Prognostic Marker and Is Associated with TNF Receptor-Associated Factor 2 (TRAF2) Expression in Prostate Cancer. Medical science monitor : international medical journal of experimental and clinical research 2017, 23:5504-5514.
17. Skawran B, Steinemann D, Becker T, Buurman R, Flik J, Wiese B, Flemming P, Kreipe H, Schlegelberger B, Wilkens L: Loss of 13q is associated with genes involved in cell cycle and proliferation in dedifferentiated hepatocellular carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2008, 21(12):1479-1489.
18. Paricharttanakul NM, Saharat K, Chokchaichamnankit D, Punyarit P, Srisomsap C, Svasti J: Unveiling a novel biomarker panel for diagnosis and classification of well-differentiated thyroid carcinomas. Oncology reports 2016, 35(4):2286-2296.
19. Jiang Z, Jiang J, Zhao B, Yang H, Wang Y, Guo S, Deng Y, Lu D, Ma T, Wang H et al: CPNE1 silencing inhibits the proliferation, invasion and migration of human osteosarcoma cells. Oncology reports 2018, 39(2):643-650.
20. Lian Q, Wang S, Zhang G, Wang D, Luo G, Tang J, Chen L, Gu J: HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas. Genomics, proteomics & bioinformatics 2018, 16(4):269-275.
21. Ghandi M, Huang FW, Jané-Valbuena J, Kryukov GV, Lo CC, McDonald ER, 3rd, Barretina J, Gelfand ET, Bielski CM, Li H et al: Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 2019, 569(7757):503-508.
22. Pontén F, Jirström K, Uhlen M: The Human Protein Atlas--a tool for pathology. The Journal of pathology 2008, 216(4):387-393.
23. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S: UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia (New York, NY) 2017, 19(8):649-658.
24. Menyhárt O, Nagy Á, Győrffy B: Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. Royal Society open science 2018, 5(12):181006.
25. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E et al: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery 2012, 2(5):401-404.
26. Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L et al: COSMIC: somatic cancer genetics at high-resolution. Nucleic acids research 2017, 45(D1):D777-d783.
27. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS: TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer research 2017, 77(21):e108-e110.
28. Vasaikar SV, Straub P, Wang J, Zhang B: LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic acids research 2018, 46(D1):D956-d963.
29. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. CA: a cancer journal for clinicians 2016, 66(1):7-30.
30. Pan JJ, Javle M, Thinn MM, Hsueh CT, Hsueh CT: Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma. Hepatic medicine : evidence and research 2010, 2:147-155.
31. Zhu AX, Duda DG, Sahani DV, Jain RK: HCC and angiogenesis: possible targets and future directions. Nature reviews Clinical oncology 2011, 8(5):292-301.
32. Wei KR, Yu X, Zheng RS, Peng XB, Zhang SW, Ji MF, Liang ZH, Ou ZX, Chen WQ: Incidence and mortality of liver cancer in China, 2010. Chinese journal of cancer 2014, 33(8):388-394.
33. de Lope CR, Tremosini S, Forner A, Reig M, Bruix J: Management of HCC. Journal of hepatology 2012, 56 Suppl 1:S75-87.
34. Finn RS: Advanced HCC: emerging molecular therapies. Minerva gastroenterologica e dietologica 2012, 58(1):25-34.
35. Bruix J, Gores GJ, Mazzaferro V: Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 2014, 63(5):844-855.
36. Cheal Yoo J, Park N, Lee B, Nashed A, Lee YS, Hwan Kim T, Yong Lee D, Kim A, Mi Hwang E, Yi GS et al: 14-3-3γ regulates Copine1-mediated neuronal differentiation in HiB5 hippocampal progenitor cells. Experimental cell research 2017, 356(1):85-92.
37. Yoo JC, Park N, Choi HY, Park JY, Yi GS: JAB1 regulates CPNE1-related differentiation via direct binding to CPNE1 in HiB5 hippocampal progenitor cells. Biochemical and biophysical research communications 2018, 497(1):424-429.
38. Manning BD, Toker A: AKT/PKB Signaling: Navigating the Network. Cell 2017, 169(3):381-405.
39. Mundi PS, Sachdev J, McCourt C, Kalinsky K: AKT in cancer: new molecular insights and advances in drug development. British journal of clinical pharmacology 2016, 82(4):943-956.
40. Cheon DJ, Orsulic S: Mouse models of cancer. Annual review of pathology 2011, 6:95-119.
41. Singh M, Johnson L: Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clinical cancer research : an official journal of the American Association for Cancer Research 2006, 12(18):5312-5328.
42. Hay N: The Akt-mTOR tango and its relevance to cancer. Cancer cell 2005, 8(3):179-183.
43. Kim TH, Sung SE, Cheal Yoo J, Park JY, Yi GS, Heo JY, Lee JR, Kim NS, Lee DY: Copine1 regulates neural stem cell functions during brain development. Biochemical and biophysical research communications 2018, 495(1):168-173.
44. Tang H, Zhu J, Du W, Liu S, Zeng Y, Ding Z, Zhang Y, Wang X, Liu Z, Huang J: CPNE1 is a target of miR-335-5p and plays an important role in the pathogenesis of non-small cell lung cancer. Journal of experimental & clinical cancer research : CR 2018, 37(1):131.
45. Tomczak K, Czerwińska P, Wiznerowicz M: The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemporary oncology (Poznan, Poland) 2015, 19(1a):A68-77.
46. Blackford AN, Jackson SP: ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. Molecular cell 2017, 66(6):801-817.
47. Gorecki L, Andrs M, Korabecny J: Clinical Candidates Targeting the ATR-CHK1-WEE1 Axis in Cancer. Cancers 2021, 13(4).
48. Brown EJ, Baltimore D: ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes & development 2000, 14(4):397-402.
49. Wiest J, Clark AM, Dai W: Intron/exon organization and polymorphisms of the PLK3/PRK gene in human lung carcinoma cell lines. Genes, chromosomes & cancer 2001, 32(4):384-389.
50. Huang L, Huang L, Li Z, Wei Q: Molecular Mechanisms and Therapeutic Potential of miR-493 in Cancer. Critical reviews in eukaryotic gene expression 2019, 29(6):521-528.
51. Zhou S, Cui Y, Yu D, Liang J, Zhang M, Ye W: MicroRNA-381 enhances radiosensitivity in esophageal squamous cell carcinoma by targeting X-linked inhibitor of apoptosis protein. OncoTargets and therapy 2017, 10:2527-2538.
52. Wen Q, Zhou C, Xiong W, Su J, He J, Zhang S, Du X, Liu S, Wang J, Ma L: MiR-381-3p Regulates the Antigen-Presenting Capability of Dendritic Cells and Represses Antituberculosis Cellular Immune Responses by Targeting CD1c. Journal of immunology (Baltimore, Md : 1950) 2016, 197(2):580-589.
53. Yang X, Ruan H, Hu X, Cao A, Song L: miR-381-3p suppresses the proliferation of oral squamous cell carcinoma cells by directly targeting FGFR2. American journal of cancer research 2017, 7(4):913-922.
54. Chan Y, Yu Y, Wang G, Wang C, Zhang D, Wang X, Wang Z, Jian W, Zhang C: Inhibition of MicroRNA-381 Promotes Tumor Cell Growth and Chemoresistance in Clear-Cell Renal Cell Carcinoma. Medical science monitor : international medical journal of experimental and clinical research 2019, 25:5181-5190.
55. Qiao G, Li J, Wang J, Wang Z, Bian W: miR‑381 functions as a tumor suppressor by targeting ETS1 in pancreatic cancer. International journal of molecular medicine 2019, 44(2):593-607.
56. Liang HQ, Wang RJ, Diao CF, Li JW, Su JL, Zhang S: The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop. Oncotarget 2015, 6(30):29413-29427.
57. Xia B, Li H, Yang S, Liu T, Lou G: MiR-381 inhibits epithelial ovarian cancer malignancy via YY1 suppression. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016, 37(7):9157-9167.
58. Tian C, Li J, Ren L, Peng R, Chen B, Lin Y: MicroRNA-381 serves as a prognostic factor and inhibits migration and invasion in non-small cell lung cancer by targeting LRH-1. Oncology reports 2017, 38(5):3071-3077.
59. Kent LN, Bae S, Tsai SY, Tang X, Srivastava A, Koivisto C, Martin CK, Ridolfi E, Miller GC, Zorko SM et al: Dosage-dependent copy number gains in E2f1 and E2f3 drive hepatocellular carcinoma. The Journal of clinical investigation 2017, 127(3):830-842.